Partner Kevin Fitzgerald was quoted in a HealthLeaders Magazine article, “Premiums Likely to Rise, More Insurers Will Leave Exchanges,” covering the uncertainty of subsidies, employee health benefits and viability of the individual market through the implementation of the Affordable Care Act under the Trump administration.
Fitzgerald explained that “uncertainty about whether ‘repeal and replace’ would pass in some form has merely been replaced by new uncertainty around cost-sharing reductions and profitability … without cost-sharing reduction payments, there will likely be no sustainable individual market.”
Fitzgerald explained that “uncertainty about whether ‘repeal and replace’ would pass in some form has merely been replaced by new uncertainty around cost-sharing reductions and profitability … without cost-sharing reduction payments, there will likely be no sustainable individual market.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”